A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
Annals of Oncology, 06/15/2012
Kindler HL et al. – Ganitumab combined with gemcitabine had tolerable toxicity and showed trends toward an improved 6–month survival rate and overall survival. Additional investigation into this combination is warranted. Conatumumab combined with gemcitabine showed some evidence of activity as assessed by the 6–month survival rate.